annb0t
Top 20
Telix Pharmaceuticals Limited
MELBOURNE, Australia, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a Phase II trial exploring the clinical utility of Telixâs first-in-class investigational PET1 agent, TLX250-CDx (89Zr-girentuximab) in recurrent clear cell renal cell carcinoma (ccRCC) after surgery.
âCA-NINEâ2 â led by Professor Brian Shuch at University of California, Lo...
>>> Read more: First Patient Dosed in Phase II âCA-NINEâ Trial of TLX250-CDx for Detection of Recurrent Kidney Cancer After Surgery
MELBOURNE, Australia, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a Phase II trial exploring the clinical utility of Telixâs first-in-class investigational PET1 agent, TLX250-CDx (89Zr-girentuximab) in recurrent clear cell renal cell carcinoma (ccRCC) after surgery.
âCA-NINEâ2 â led by Professor Brian Shuch at University of California, Lo...
>>> Read more: First Patient Dosed in Phase II âCA-NINEâ Trial of TLX250-CDx for Detection of Recurrent Kidney Cancer After Surgery
